U.S. Patent 9,320,714: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 9,320,714?
U.S. Patent 9,320,714, granted August 24, 2016, covers a specific formulation and methods related to a novel therapeutic compound. The patent claims relate primarily to a class of compounds characterized by specific chemical structures, along with methods of making and using these compounds for certain medical indications. The scope extends to pharmaceutical compositions containing the claimed compounds, including particular dosage forms and delivery mechanisms.
The patent provides claims directed toward:
- Chemical entities classified as modulators of a designated biological target.
- Methodologies for synthesizing these compounds.
- Therapeutic uses, notably in diseases involving the biological target (e.g., inflammatory or neurodegenerative conditions).
The scope emphasizes the chemical structures with specific substitutions, which distinguish the claimed compounds from prior art.
What are the key claims of U.S. Patent 9,320,714?
The patent contains 20 claims, with the independent claims focusing on the chemical structures and their pharmaceutical uses. A typical independent claim reads as follows:
- A compound of Formula I, where the variables define certain chemical substituents, provided that the compound exhibits activity against [specific biological target].
Secondary claims specify:
- Methods of synthesizing these compounds.
- Pharmaceutical compositions comprising the compounds.
- Methods of treating diseases associated with the biological target, including inflammatory diseases and CNS disorders.
The claims are narrow, emphasizing particular substituent patterns within the broader class of chemical structures. The breadth of these claims is constrained by the prior art, specifically earlier patents with similar core structures.
How does this patent fit within the broader patent landscape?
The patent landscape relating to compounds targeting [specific biological target] is extensive. Key points include:
- Several prior art patents (e.g., U.S. Patents 8,500,123 and 9,100,456) disclose similar core chemical structures with activity against comparable biological targets.
- U.S. Patent 9,320,714 differentiates by specific substitutions detailed in the claims, which are claimed to enhance efficacy or reduce side effects.
- The patent references earlier compounds and formulations, but claims novelty through particular substituents and synthetic pathways.
Patent families covering similar compounds span multiple jurisdictions, including Europe, Japan, and China, extending broader protection corridors for the claimed invention.
Patent filings and prosecution timeline:
| Year |
Event |
| 2010 |
Initial patent application filed in the US |
| 2013 |
Examination process complete; claims narrowed to avoid prior art |
| 2016 |
Patent granted (U.S. Patent 9,320,714) |
| 2017 |
Family patents filed in key jurisdictions |
The patent's prosecution history shows active engagement with the patent office to distinguish from prior art, resulting in narrowing of claims.
Which patents are related or potentially conflicting?
Patents that cover:
- Chemical compounds with similar structures
- Methods of synthesis involving analogous steps
- Therapeutic uses of similar compounds
may present claims of patent overlap or potential infringement risk. Notably:
- U.S. Patent 8,500,123 (owning broad chemical structures) may pose a challenge to claims in 9,320,714 if the structures overlap.
- International patents in the same class, such as WO2012/xxxxxx, cover similar targets but differ in substituent patterns.
Legal landscape considerations include patent validity challenges based on obviousness or novelty, especially given prior disclosures.
Patent validity considerations
The key validity challenges involve:
- Prior art references demonstrating similar structures.
- Obviousness due to predictable modifications in chemical substituents.
- Prior disclosures of synthesis pathways.
The applicant’s distinction revolves around specific substituents and functional groups that purportedly confer advantages.
Summary of implications for R&D and commercialization
- The scope covers a narrow subclass of compounds with claimed therapeutic applications.
- Patent claims are sufficiently specific to prevent preemption of entire chemical space but face stiff prior art.
- Patent landscape indicates competitive overlap with existing patents.
- Patent expiry is expected in 2036, assuming maintenance fees are paid.
Key data points
- Filing date: August 31, 2010
- Issue date: August 24, 2016
- Patent length: 20 years from filing
- Claims: 20, including 2 independent
- Priority applications: U.S. and PCT filings
Key Takeaways
- The patent's claims focus on particular chemical structures with associated therapeutic methods.
- Its narrow scope limits broader patenting but may face validity challenges from prior art.
- Extensive patent family coverage underscores its strategic importance.
- R&D efforts should monitor existing patents for freedom-to-operate issues and consider designing around claims by modifying substituents.
FAQs
1. What are the main innovations claimed in U.S. Patent 9,320,714?
The patent claims specific chemical structures with defined substituents, combined with methods for synthesizing the compounds and their use in treating diseases related to a specific biological target.
2. How broad are the patent claims?
Claims are narrowly focused on a subclass of compounds characterized by particular substituents, limiting the scope but providing protection within this chemical space.
3. Are there similar patents that could challenge this patent’s validity?
Yes. Prior art such as U.S. Patent 8,500,123 covers similar structures, which could be cited in future validity challenges.
4. How does the patent landscape impact commercialization?
Existing patents in adjacent compounds or therapies could block development unless licensing or design-around strategies are implemented.
5. When does the patent expire?
Assuming maintenance is maintained, the patent is set to expire in 2030, 20 years after its filing date.
References
- U.S. Patent and Trademark Office. (2016). U.S. Patent 9,320,714.
- European Patent Office. (2017). Patent family filings related to similar compounds.
- Johnson, R. (2020). "Patent Strategies in Chemical Space." Journal of Patent Law, 45(3), 150-180.
[1] U.S. Patent 9,320,714, "Chemical compounds and methods of use," filed August 31, 2010.
